Effect of erythropoiesis-stimulating agents on the progression of chronic kidney disease: a retrospective study

Effect of erythropoiesis-stimulating agents on the progression of chronic kidney disease: a retrospective study - Effect of ESA on the progression of CKD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000013311

Enrollment

Registered

2014-03-03

Start date

2014-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease patients with renal anemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CKD patients with renal anemia who received ESA therapy at Kyushu University Hospital from January 2005 to October 2009

Exclusion criteria

Exclusion criteria: 1. Patients with apparent hemorrhagic lesion 2. Patients with hematologic disease (e.g. leukemia, malignant lymphoma, myelodysplastic syndrome, aplastic anemia) 3. Patients with apparent chronic inflammation (e.g. rheumatoid arthritis, inflammatory bowel disease) 4. Patients with complication of malignant tumor

Design outcomes

Primary

Measure	Time frame
Change in the deterioration rate of estimated glomerular filtration rate (eGFR) after administration of ESA	—

Countries

Japan

Contacts

Public ContactKazuhiko Tsuruya

Graduate School of Medical Sciences, Kyushu University Department of Integrated Therapy for Chronic Kidney Disease

tsuruya@intmed2.med.kyushu-u.ac.jp092-642-5843

Outcome results